resulted in the use of increased dosages of busulfan in small children. 4, 5 It is conceivable that an optimal anti-leukemic effect requires a minimum concentration of busulfan. HowThe aim of this study was to investigate the importance of busulfan concentrations for short-and long-term surever, to our knowledge no study has been published linking low busulfan concentrations with an increased relapse risk. vival in autologous (ABMT) and allogeneic (BMT) bone marrow transplant recipients. One hundred and sevConversely, high busulfan concentrations might be associated with increased toxicity. 6 For example, we have preenty-three patients were included in the study; 87 ABMT and 85 BMT patients. All patients received buviously shown that a high busulfan concentration is correlated to permanent alopecia in BMT patients. 7 Thus, it is sulfan 1 mg/kg four times daily for 4 days followed by cyclophosphamide 60 mg/kg/day for 2 days. Busulfan possible that optimization of the busulfan-cyclophosphamide regimen might improve the results concerning both concentrations were measured and the mean concentration calculated for each patient. There was no differefficacy and toxicity. The aims of this study were therefore to investigate the importance of busulfan concentrations for ence in busulfan concentrations between BMT and ABMT patients. Patients who died before day 100 had short-and long-term survival in autologous (ABMT) and allogeneic (BMT) bone marrow transplant recipients. significantly higher busulfan concentrations than patients surviving beyond day 100 (719 ng/ml vs 589 ng/ml; P Ͻ 0.02). BMT patients who had busulfan concentrations in the highest quartile had significantly Patients and methods worse disease-free survival (DFS) and survival compared to other patients. The transplant-related morOne hundred and seventy-two patients were included in the study from the BMT and ABMT programs at the University talities (TRM) at 100 days were 29 and 14% in patients in the highest quartile and remaining patients, respecthospitals of Huddinge, Lund and Uppsala. Eighty-seven patients had undergone ABMT and 85 BMT. All BMT ively. There was no difference in relapse incidence. High busulfan concentrations were associated with increased patients had received marrow from HLA-matched family donors.
8,9
circadian rhythmicity, bioavailability, and disease status is well established. 1, 2 Thus it would be logical that varying Busulfan concentration determination concentrations of busulfan might result in different outcomes. These different outcomes would include both toxBlood samples were drawn from permanently placed cenicity and relapse incidences. Low busulfan concentrations tral venous lines. Two sampling schedules were used in in children have been associated with an increased risk of the study. Forty-eight patients were sampled immediately rejection in allogeneic transplant recipients. 3, 4 This has before busulfan doses 4 to 16 and the remaining 124 patients from doses 7 to 16, both schedules representing the minimum concentration at the steady-state level. These
Correspondence: Dr P Ljungman, Dept of Hematology, Huddinge Univerlevels were chosen because of the high uncertainty in the sity Hospital, S-14186 Huddinge, Sweden Received 11 January 1997; accepted 14 July 1997 determination of AUC from the first dose. Busulfan concen-trations for each patient were calculated from dose 4 or dose 7 to 16. The mean minimum concentration was calculated from samples taken immediately before each dose. All patients had all scheduled samples collected and analyzed. Blood was collected in glass tubes with 150 units of heparin. Plasma was separated by centrifugation at 2000 g and stored in −20°C until analysis. Busulfan in plasma was first converted to 1,4-diiodobutane by a reaction with sodium iodide in the presence of n-heptane and was thereafter measured by gas chromatography with electron capture detection.
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Supportive care such as prophylaxis against infections and VOD, isolation procedures, anti-emetic protocols and transfusion policy was given according to each center's routines. In most patients, cyclosporine and short course methotrexate were used as prophylaxis against GVHD.
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Statistics
Our hypothesis was that high busulfan concentrations mediated an increased risk for TRM, and that low busulfan concentrations due to a poor antileukemic effect were associated with an increased risk of relapse. Furthermore, we believed it was likely that this effect was not linear. Two models were constructed for analysis. In the first model, busulfan concentrations were analyzed as a continuous variable. Thereafter, a Cox regression model was constructed which included stage of disease, patient age and busulfan concentrations as variables. All analyses were performed for the total study group and for ABMT and BMT patients, respectively.
In the second model we attempted to analyze for the possibility that high busulfan concentrations were disproportionally associated with increased mortality or low bu- relapse. Therefore, busulfan concentrations were divided
Lines represent highest and lowest quartiles, respectively into quartiles. Kaplan-Meier curves were then constructed for each of the quartile groups regarding survival, DFS and TRM. Shapes of the curves were then studied and there increasing busulfan concentrations with older age seemed to be a breakpoint between the highest quartile (r 2 = 0.12; P = 0.07). group and the other groups. Therefore, for analysis purposes, the three lower quartile groups were combined and survival, DFS and TRM compared between the highest Busulfan concentrations and outcome quartile group, and the combined lower three quartile
In the model where busulfan was used as a continuous varigroups by log-rank test. Finally, a Cox regression model able, busulfan concentrations were associated with TRM was constructed including stage of disease, patient age and and overall survival but not with DFS. In the quartile the quartiles of busulfan concentrations as variables. All model, patients in the highest quartile group (busulfan conanalyses were performed for the total study group and for centration у721 ng/ml) had significantly increased TRM ABMT and BMT patients, respectively.
during the first year after transplantation (29 vs 14%); P = 0.01) while there was no difference in the risk for relapse (P = 0.86). The causes of death during the first 12 Results months after transplantation are shown in Table 1 . Eighteen of 44 (41%) patients in the highest busulfan concentration quartile died during the first 12 months after transplantation The median busulfan concentration measured for the entire patient group was 593 ng/ml (range 111-1512). There was compared to 33/173 (19%) of patients with busulfan concentration in the lower three quartiles. Transplant-related no difference in busulfan concentrations between BMT and ABMT patients (BMT median 596 ng/ml, range 168-1512; causes were twice as common (66 vs 33%) as the cause of death in the highest quartile group. The increased risk for ABMT median 591 ng/ml, range 111-1199). The distribution of the busulfan concentrations in BMT and ABMT TRM in the highest quartile group resulted in a decreased overall survival (P = 0.03) and a decreased DFS (P = 0.02) recipients is shown in Figure 1 . There was a trend for Table 1 Causes of death during the first 12 months after transplanand 64% (P = 0.03; Figure 3) between patients in the highest quartile of busulfan concentrations and the other quartile groups regardless of whether all patients were analyzed together or split according to the stage of leukemia. compared to patients with lower concentrations. The survivals at 3 years after transplantation were 40 and 56% in the highest quartile and the three lower quartile groups, respectively (P = 0.05). The corresponding DFS were 37 Discussion and 51%, respectively, P = 0.03). Furthermore, patients who died before day 100 had significantly higher busulfan
Results from randomized studies comparing cyclophosphamide/TBI and busulfan/cyclophosphamide as conconcentrations than patients surviving beyond day 100 (719 vs 589 ng/ml; P Ͻ 0.02) indicating that the main factor ditioning regimen for allogeneic BMT have shown comparable long-term survivals in patients with CML and early influencing survival was TRM.
Since busulfan concentrations are highly age dependent, stages of acute leukemia. 8, 12 However, a study of AML patients transplanted in first complete remission showed a TRM and DFS were analyzed in relation to age. Age did not influence TRM either when analyzed as a continuous survival advantage for patients conditioned with TBI compared to busulfan. Previous studies have shown that busulvariable or grouped above and below 10 years of age. In a Cox regression model including stage of disease (early fan containing regimens were associated with increased risk of VOD, in particular if combined with methotrexate and or intermediate stage leukemia, age as a continuous variable and busulfan concentrations analyzed as highest vs the cyclosporine as GVHD prophylaxis.
13,14
The results of our study showed that high busulfan conother three quartiles), stage of disease and busulfan concentration were independently associated with DFS and TRM centrations were independently associated with overall survival, TRM and DFS. The negative effect of high busulfan while age was not.
concentrations was strongest in the BMT patients in whom the increased TRM translated into lower DFS and overall BMT patients survival. In ABMT patients, busulfan concentrations influenced TRM but this did not translate into a worse outcome. In BMT patients, busulfan concentrations were associated with survival, DFS and TRM both in univariate and multi-
The increased TRM could be explained by several contributing factors, the most important probably being VOD. variate analysis. However, there was no association between busulfan concentrations and relapse.
We have previously shown that there was an association between VOD and increased busulfan concentrations BMT patients who had busulfan concentrations in the highest quartile had significantly higher TRM than patients although it was not significant in multivariate analysis when stage of leukemia was included as a factor in the model.
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with lower busulfan concentrations. The TRM at 100 days were 41 and 18% in patients in the highest quartile group The analysis presented in the present paper was based on a larger patient group and included all causes of TRM and the lower three quartile groups, respectively (P = 0.01; Figure 2 ). TRM was significantly increased in patients with which might explain the different results compared to our previous study. The entire negative effect of high busulfan high busulfan concentrations transplanted for early stage leukemia (27 vs 7%; P = 0.01) while there was no differconcentrations was found in the BMT patients while there was no effect whatsoever in the ABMT patients. Most ence in patients transplanted for late stage leukemia (43 vs 57%; P = 0.54).
BMT patients received the combination of methotrexate and cyclosporine for GVHD prophylaxis which was preThere were no differences in the risks for relapse between the high or low busulfan concentrations regardless viously shown to be associated with an increased risk for VOD. 14 One conclusion of our study might be that this of whether the highest quartile group were compared to other three groups or the lowest quartile group compared combination can be used, since it is very effective for the prevention of severe GVHD, if the busulfan concentrations to the higher three groups.
The increased TRM resulted in lower DFS and survival are monitored and the dose adjusted according to the results. Grochow 6 showed previously that such a dose compared to other patients. Overall survivals at 3 years were 49 and 66% (P = 0.08) and DFS at 3 years were 47 adjustment could reduce the risk for VOD. Thus, our data support the conclusions by Grochow and Slattery et al that How high must a busulfan concentration be to be too high? This is obviously important in order to adjust the busulfan concentration measurements are useful for determining the risk for severe transplant-related complibusulfan dosage. We analyzed this question by the model where we compared quartiles of busulfan concentrations cations and contrast with the results from Schuler et al who could not in a small series of patients find any effect of and found that in BMT patients a busulfan concentration above 721 ng/ml was associated with an increased TRM busulfan kinetic parameters on VOD. 16, 17 However, the main clinical use of our study is to adjust and individualize and a lower survival, while in ABMT patients this level was associated with an increased TRM. Thus, it seems that busulfan dosage based on the limited sampling models, which were suggested by many authors. 5, 6, 18 high concentrations of busulfan can cause severe toxicity. 
